What are the best anticoagulation options in terms of cost-benefit-risk for oncology patients with venous thrombotic disease and risk of gastrointestinal bleeding due to gastric tumor?
Year: 2026
Type: article
Abstract: Direct evidence supports LMWH as the preferred anticoagulation option for oncology patients with gastric tumors due to its lower bleeding risk compared to direct oral anticoagulants.
Author: Tripdatabase
Language: English
Subfield: Internal Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236354895
